Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
Authors:
- Wan WangWWWan Wang
- Kaoru TsuchiyaKTKaoru Tsuchiya
- Masayuki KurosakiMKMasayuki Kurosaki
- Yutaka YasuiYYYutaka Yasui
- Kento InadaKIKento Inada
- Sakura KirinoSKSakura Kirino
- Koji YamashitaKYKoji Yamashita
- Shuhei SekiguchiSSShuhei Sekiguchi
- Yuka HayakawaYHYuka Hayakawa
- Leona OsawaLOLeona Osawa
- Mao OkadaMOMao Okada
- Mayu HiguchiMHMayu Higuchi
Open Access
Abstract
Background: We aimed to explore the relative dose intensity (RDI) and post-regorafenib treatments in regorafenib therapy. Methods: The medical records of 38 patients treated with regorafenib between July 2017 and June 2019 at our institution were collected. The RDI of regorafenib for the first month (1M-RDI) was calculated. Results: The overall survival (OS) and progression-free survival (PFS) were 12.4 and 3.7 months. The objective response rate and disease control rate were 13.2% and 71.1%. The median total dose of regorafenib in the first month was 2080 mg (240–3360 mg), and the median 1M-RDI was 61.9% (7.1–100%). Patients with 1M-RDI ≥ 50% showed significantly longer OS and PFS than patients with 1M-RDI < 50% (HR 0.19, 95% CI 0.08–0.48, p = 0.0004 and HR 0.2, 95% CI 0.08–0.52, p = 0.0008). A 1M-RDI ≥ 50% (HR 0.18, 95% CI 0.06–0.55, p = 0.002) and hand–foot skin reaction (HR 0.03, 95% CI 0.008–0.16, p < 0.0001) were independently associated with OS. Post-regorafenib therapies were performed in 19 (86.4%) of 22 patients who had stopped regorafenib due to disease progression. Conclusion: A 1M-RDI ≥ 50% is clinically significant. Post-regorafenib therapies are commonly performed in real-world practice.Keywords
This publication has 30 references indexed in Scilit:
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer ModelMolecular Cancer Therapeutics, 2013
- Genetic predisposition of hand‐foot skin reaction after sorafenib therapy in patients with hepatocellular carcinomaCancer, 2012
- One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patientsEuropean Journal of Cancer, 2011
- Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInternational Journal of Cancer, 2010
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- Dose-Intense Chemotherapy Every 2 Weeks With Dose-Intense Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone May Improve Survival in Intermediate- and High-Grade Lymphoma: A Phase II Study of the Southwest Oncology Group (SWOG 9349)Journal of Clinical Oncology, 2003